The company had sought approval for dasiglucagon for the treatment and prevention of hypoglycaemia in infants with congenital hyperinsulinism. Credit: Gorodenkoff/Shutterstock.

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Zealand Pharma, declining the approval of dasiglucagon for the treatment and prevention of hypoglycaemia in infants with congenital hyperinsulinism (CHI).

The CRL, which pertains to Part 1 of the new drug application (NDA) for patients aged seven days and older, cites the need for a reinspection at a third-party manufacturing facility.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This regulatory decision is linked to the timing of a reinspection at a contract manufacturing site that concluded in August/September 2024.

The facility, responsible for producing dasiglucagon, has not received its inspection classification post-reinspection.

Although a previous inspection had identified deficiencies, they were not related to dasiglucagon and had been addressed by the time of the latest reinspection.

See Also:

The CRL did not raise any concerns regarding the clinical data or the safety profile of dasiglucagon.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zealand Pharma’s NDA for dasiglucagon is currently undergoing a two-part regulatory review.

While Part 1 involved dosing for up to three weeks, Part 2 will cover usage beyond that period.

The FDA has requested additional analyses from existing continuous glucose monitoring data collected during Phase III clinical trials to support the use of dasiglucagon in CHI for extended periods.

Zealand Pharma anticipates submitting the required data by the end of 2024.

Zealand Pharma chief medical officer David Kendall said: “We at Zealand Pharma are acutely aware of the significant unmet medical need for newborns and children with congenital hyperinsulinism who have either no or very limited treatment options today.

“We are committed to working with the FDA and our third-party manufacturing partner to bring dasiglucagon to patients living with this devastating disease in the months ahead.”